Targets › AKR1C3
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Oct 2027.
Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 17beta-hydroxysteroids, but also 3alpha- and 20alpha-hydroxysteroids. (UniProt, P42330)
Open in Phaseline: the race on AKR1C3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhejiang Hisun Pharmaceutical | AST-3424 AKR1C3 inhibitor | AKR1C3 | Phase 2 | HCC - Hepatocellular Carcinoma | Oct 2027 |
| SWOG Cancer Research Network | OBI-3424 AKR1C3-activated prodrug | AKR1C3 | Phase 1 | Recurrent T Acute Lymphoblastic Leukemia | Aug 2028 |
Recurrent T Acute Lymphoblastic Leukemia (1) HCC - Hepatocellular Carcinoma (1)
protein or peptide (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.